



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/735,118
				Filing Date	December 11, 2003
				First Named Inventor	Sarah s. Bacus
				Art Unit	1642
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	
<input style="width: 150px; height: 30px; margin: 0 auto;" type="button" value="Print"/>					

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ¹ – Number ¹ – Kind Code ¹ (if known)	MM-DD-YYYY			
		EP 0 656367 A1	06/07/1995	Becton Dickinson and Company	1-83	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/735,118
				Filing Date	December 11, 2003
				First Named Inventor	Sarah S. Bacus
				Art Unit	1634
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	6270-701.201

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		BACUS, S.S., et al., "HER2/Neu Oncogene Expression and Proliferation in Breast Cancers," <i>American Journal of Pathology</i> , (1990), VOL. 137, No. 1, pages 103-111, XP-000998483.			
		GUILLERNARD, V., et al., "Selective Delivery of Chemotherapeutics to Cancer Cells Via Growth Factor Receptors: Towards the Development of Smart Chemotherapeutic Agents, <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> , (2002), page 76, XP-001180581.			
		BACUS, S. et al, "Differences in Reponse of Breast Cancer Molecular Profiles of Patients likely to Respond Either to erbB Tyrosine Kinase Inhibitors or to erbB Targeted Antibodies," <i>Breast Cancer Research and Treatment</i> (2003), Vol. 82, No. suppl. 1, pages S-72-S-73, XP009034953.			
		LEITZEL, K., et al., "Increased Serum IGF Receiptor (IGF-IR) in Patients With Elevated Serum HER-2/neu," <i>Breast Cancer Research and Treatment</i> (2003), Vol. 82, No. suppl. 1, pages S-94, XP009034954.			
Examiner signature		/Laura B. Goddard/		Date Considered	03/26/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.